
ALC Stock Forecast & Price Target
ALC Analyst Ratings
Bulls say
Alcon is positioned favorably because its core end markets continue to benefit from premiumization, new product launches, and share gains in both Vision Care and Surgical, even as broader market growth remains softer than historical levels. In 3Q26, revenue rose 6% on a constant-currency basis, core EPS beat estimates by 4%, gross margin expanded to 65.7%, and core operating margin improved to 21.8%, showing strong operating leverage despite mixed top-line execution. Leadership in contact lenses, strength from PanOptix Pro, Unity, Tryptyr, and Valeda, plus 111% TTM free cash flow conversion support the view that Alcon can sustain mid-single-digit growth and double-digit EPS growth.
Bears say
Alcon is facing a weaker fundamental setup as its revenue growth appears to be slowing from management’s 2026 guidance to a likely 2027 deceleration, with the bear case centered on flat-to-low-single-digit growth and limited operating expense leverage. Soft 3Q26 results reinforced the concern, as +5% CC sales missed expectations, implantables fell -2% CC, IOLs declined -1% y/y, and equipment growth of +11% CC still lagged estimates, suggesting competitive pressure in key products like PureSee and uncertain uptake of newer offerings. With costs rising faster than expected, margins stuck around the low-20s, and management’s guidance only partly supported by M&A and Neurotech, the stock looks likely to remain range-bound rather than re-rate higher.
This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.
ALC Analyst Forecast & Price Prediction
Start investing in ALC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Alcon Inc. - Registered Shares (ALC) Forecast
ALC Analyst Forecast & Price Prediction
Start investing in ALC
Order type
Buy in
Order amount
Est. shares
0 shares